Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362737243> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4362737243 abstract "<div>Abstract<p>Combination therapies consisting of immune checkpoint inhibitors plus anti-VEGF therapy show enhanced antitumor activity and are approved treatments for patients with renal cell carcinoma (RCC). The immunosuppressive roles of VEGF in the tumor microenvironment are well studied, but those of FGF/FGFR signaling remain largely unknown. Lenvatinib is a receptor tyrosine kinase inhibitor that targets both VEGFR and FGFR. Here, we examine the antitumor activity of anti-PD-1 mAb combined with either lenvatinib or axitinib, a VEGFR-selective inhibitor, in RCC. Both combination treatments showed greater antitumor activity and longer survival in mouse models versus either single agent treatment, whereas anti-PD-1 mAb plus lenvatinib had enhanced antitumor activity compared with anti-PD-1 mAb plus axitinib. Flow cytometry analysis showed that lenvatinib decreased the population of tumor-associated macrophages and increased that of IFNγ-positive CD8<sup>+</sup> T cells. Activation of FGFR signaling inhibited the IFNγ-stimulated JAK/STAT signaling pathway and decreased expression of its target genes, including <i>B2M</i>, <i>CXCL10</i>, and <i>PD-L1</i>. Furthermore, inhibition of FGFR signaling by lenvatinib restored the tumor response to IFNγ stimulation in mouse and human RCC cell lines. These preclinical results reveal novel roles of tumor FGFR signaling in the regulation of cancer immunity through inhibition of the IFNγ pathway, and the inhibitory activity of lenvatinib against FGFRs likely contributes to the enhanced antitumor activity of combination treatment comprising lenvatinib plus anti-PD-1 mAb.</p>Significance:<p>FGFR pathway activation inhibits IFNγ signaling in tumor cells, and FGFR inhibition with lenvatinib enhances antitumor immunity and the activity of anti-PD-1 antibodies.</p></div>" @default.
- W4362737243 created "2023-04-11" @default.
- W4362737243 creator A5003415756 @default.
- W4362737243 creator A5006210040 @default.
- W4362737243 creator A5008447763 @default.
- W4362737243 creator A5039847095 @default.
- W4362737243 creator A5044623118 @default.
- W4362737243 creator A5051867714 @default.
- W4362737243 creator A5060408005 @default.
- W4362737243 creator A5062679115 @default.
- W4362737243 creator A5079407472 @default.
- W4362737243 creator A5079712544 @default.
- W4362737243 creator A5081046605 @default.
- W4362737243 creator A5081072346 @default.
- W4362737243 creator A5084998090 @default.
- W4362737243 creator A5091434088 @default.
- W4362737243 date "2023-04-10" @default.
- W4362737243 modified "2023-10-18" @default.
- W4362737243 title "Data from Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies" @default.
- W4362737243 doi "https://doi.org/10.1158/0008-5472.c.6570578" @default.
- W4362737243 hasPublicationYear "2023" @default.
- W4362737243 type Work @default.
- W4362737243 citedByCount "0" @default.
- W4362737243 crossrefType "posted-content" @default.
- W4362737243 hasAuthorship W4362737243A5003415756 @default.
- W4362737243 hasAuthorship W4362737243A5006210040 @default.
- W4362737243 hasAuthorship W4362737243A5008447763 @default.
- W4362737243 hasAuthorship W4362737243A5039847095 @default.
- W4362737243 hasAuthorship W4362737243A5044623118 @default.
- W4362737243 hasAuthorship W4362737243A5051867714 @default.
- W4362737243 hasAuthorship W4362737243A5060408005 @default.
- W4362737243 hasAuthorship W4362737243A5062679115 @default.
- W4362737243 hasAuthorship W4362737243A5079407472 @default.
- W4362737243 hasAuthorship W4362737243A5079712544 @default.
- W4362737243 hasAuthorship W4362737243A5081046605 @default.
- W4362737243 hasAuthorship W4362737243A5081072346 @default.
- W4362737243 hasAuthorship W4362737243A5084998090 @default.
- W4362737243 hasAuthorship W4362737243A5091434088 @default.
- W4362737243 hasBestOaLocation W43627372432 @default.
- W4362737243 hasConcept C2776264508 @default.
- W4362737243 hasConcept C2776539811 @default.
- W4362737243 hasConcept C2778019345 @default.
- W4362737243 hasConcept C2778695046 @default.
- W4362737243 hasConcept C42362537 @default.
- W4362737243 hasConcept C502942594 @default.
- W4362737243 hasConcept C62478195 @default.
- W4362737243 hasConcept C71924100 @default.
- W4362737243 hasConcept C86803240 @default.
- W4362737243 hasConcept C95444343 @default.
- W4362737243 hasConcept C98274493 @default.
- W4362737243 hasConceptScore W4362737243C2776264508 @default.
- W4362737243 hasConceptScore W4362737243C2776539811 @default.
- W4362737243 hasConceptScore W4362737243C2778019345 @default.
- W4362737243 hasConceptScore W4362737243C2778695046 @default.
- W4362737243 hasConceptScore W4362737243C42362537 @default.
- W4362737243 hasConceptScore W4362737243C502942594 @default.
- W4362737243 hasConceptScore W4362737243C62478195 @default.
- W4362737243 hasConceptScore W4362737243C71924100 @default.
- W4362737243 hasConceptScore W4362737243C86803240 @default.
- W4362737243 hasConceptScore W4362737243C95444343 @default.
- W4362737243 hasConceptScore W4362737243C98274493 @default.
- W4362737243 hasLocation W43627372431 @default.
- W4362737243 hasLocation W43627372432 @default.
- W4362737243 hasOpenAccess W4362737243 @default.
- W4362737243 hasPrimaryLocation W43627372431 @default.
- W4362737243 hasRelatedWork W1520540494 @default.
- W4362737243 hasRelatedWork W2142774159 @default.
- W4362737243 hasRelatedWork W2339755730 @default.
- W4362737243 hasRelatedWork W2416569285 @default.
- W4362737243 hasRelatedWork W2605165272 @default.
- W4362737243 hasRelatedWork W2899245424 @default.
- W4362737243 hasRelatedWork W2973451075 @default.
- W4362737243 hasRelatedWork W4250652343 @default.
- W4362737243 hasRelatedWork W4310593023 @default.
- W4362737243 hasRelatedWork W4365516835 @default.
- W4362737243 isParatext "false" @default.
- W4362737243 isRetracted "false" @default.
- W4362737243 workType "article" @default.